QIAGEN powered by

Webinars and events

Loading Events

« All Events

Cross-species comparison and validation for drug discovery and biomarker research using QIAGEN Ingenuity Pathway Analysis (IPA)

September 26, 2023 @ 1:00 pm - 2:30 pm

Some human studies may be unfeasible or unethical, making cross-species research critical for drug discovery and biomarker validation. Cross-species research is a crucial method to collect data to examine potential toxicity for a candidate drug, determine the efficacious doses that may be suitable for humans, identify potential biomarkers for a disease of interest or a therapeutic response and understand the mechanisms of disease or treatment. While animal models and humans have similar anatomy and physiology, the subtle differences among organisms in the animal kingdom need to be considered and data collected must be interpreted using a meaningful method.

Using QIAGEN IPA, you can perform comparative analyses across various animal models, even combining different time points, treatments, tissues and cell types with data generated from a wide variety of ‘omics technologies (RNA-seq, scRNA-seq, proteomics, metabolomics, etc.). In this training, you will learn how to:
1. Generate activity heatmaps and expression charts comparing different pathways and regulatory networks across different species
2. Use Activity Plot, Pattern Search and Analysis Match to compare your own data against thousands of public data pre-curated and pre-analyzed representing an array of disease states, conditions and other biological conditions
3. Create expression and correlation plots using pre-curated and pre-analyzed public data to validate and confirm findings derived from a comparison analysis

Please consider reviewing the below tutorials before this meeting.
https://qiagen.showpad.com/share/SQjinvdxIs1iGhL8H3eOd

On-demand Webinars


  • Indication expansion and drug repurposing using QIAGEN OmicSoft and Ingenuity Pathway Analysis

    Research and development for new drugs and disease treatments can be lengthy and costly. Indication expansion can help broaden the impact of a new drug that has already been through the arduous R&D process for a disease or cancer. Drug repurposing can take this concept and expand on it by looking for other diseases with similar drug target biology. The logic is if...

  • Part I: Single-cell RNA sequencing data analysis using QIAGEN CLC Genomics Workbench

    This two-part series will walk you through single-cell RNA sequencing (scRNA-seq) analysis starting with a matrix file or FASTQ files and ending with a deep understanding of key pathways, regulators and cell type signatures within your data. This session is for part I of this training. In this session, you'll learn to use QIAGEN CLC Genomics Workbench to perform se...

  • Part II: Single-cell RNA sequencing data interpretation using QIAGEN Ingenuity Pathway Analysis

    This two-part series will walk you through single-cell RNA sequencing (scRNA-seq) analysis starting with a matrix file or FASTQ files and ending with a deep understanding of key pathways, regulators and cell type signatures within your data. In this session, we'll explore how you can take your scRNA-seq differential expression results produced from QIAGEN CLC Genom...

  • Immune repertoire analysis using QIAGEN CLC Genomics Workbench

    The composition of the immune repertoire, consisting of the T cell and B cell receptors (TCR and BCR), is important for an organism's adaptive immune system and plays a pivotal role in an individual's overall health. Understanding the complex array of TCR and BCR allows for developing precision medicine and immunotherapy. Analyzing next-generation sequencing (NGS) dat...

  • Compare and contextualize your results using QIAGEN Ingenuity Pathway Analysis

    Take your QIAGEN Ingenuity Pathway Analysis (IPA) analyses to the next level by comparing them to your own analyses (different time points, treatments, cell lines, diseases and more) or to a library of over 100K precomputed datasets to find similar or opposite biological signatures. Identify key genes or entities and then explore how they are expressed across normal t...

  • Drug treatment, toxicology and target safety assessment using QIAGEN IPA and OmicSoft

    In this 90-minute training, you'll learn how to perform drug treatment, toxicology and target safety assessment-related discoveries using QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN Omicsoft Lands. Using public data from GTEx (normal tissue), GEO, cancer collections and more, you'll learn how to use Omicsoft Lands to: • Investigate a drug target or biom...